Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.

Article Details

Citation
Copy to clipboard

Steinhauser SL

Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.

Optometry. 2006 Apr;77(4):177-9.

PubMed ID
16567279 [ View in PubMed
]
Abstract

BACKGROUND: The aim of this study is to report an adverse systemic response associated with topical bimatoprost therapy. CASE REPORT: An otherwise healthy 58-year-old woman with primary open-angle glaucoma was started on bimatoprost drops once a day. Bimatoprost is a structural analog of prostaglandin F2 alpha-ethanolamide (PGF2a), a class of compounds that in systemic form has been associated with alterations in serum lipid levels. The patient subsequently experienced a significant decrease in her high-density lipoprotein (HDL) serum levels, which subsequently returned to normal on discontinuation of bimatoprost. CONCLUSIONS: This is the first published report of a possible association between topical bimatoprost therapy and decreased serum HDL levels. Because of the significantly increased risk of cardiovascular disease and morbidity associated with low HDL levels, further study is strongly indicated.

DrugBank Data that Cites this Article

Drugs